Physician profile
Anny Cheng
NPI 1396371399
$2,549.75
in general payments reported to CMS, 2019-2025
14 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.15 · 2023: $751 · 2024: $1,006 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $389.95 | 2024-2025 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $365.43 | 2024-2025 | Veritas Vision System, Tecnis Iol |
| Sight Sciences, INC. | $273.78 | 2022-2024 | Omni Surgical System |
| Abbvie INC. | $241.52 | 2024-2025 | |
| Alcon Vision LLC | $233.27 | 2023-2024 | Hydrus Microstent, Centurion |
| Amgen INC. | $176.91 | 2024 | Tepezza |
| Apellis Pharmaceuticals, INC. | $123.00 | 2023 | Syfovre |
| New World Medical,INC. | $122.91 | 2025 | Streamline, Kahook Dual Blade, Via360 |
| Ocular Therapeutix, INC. | $122.55 | 2023 | Dextenza |
| Ani Pharmaceuticals, INC. | $121.60 | 2024 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $120.65 | 2023 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Biotissue Holdings INC. | $117.23 | 2024 | |
| Horizon Therapeutics Plc | $99.59 | 2023 | Tepezza |
| Glaukos Corporation | $41.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anny Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.